Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 9;42(17):2080–2093. doi: 10.1200/JCO.23.01636

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by American Society of Clinical Oncology

Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

FIG 2. — Subgroup analysis of unweighted ORR difference per BICR in all randomly assigned patients. Two-sided 95% CI for unweighted difference was calculated using Newcombe method. ORR difference is not computed for subsets with <10 patients in at least one treatment group. ORR difference: NIVO plus RELA minus NIVO. ^aORR difference was not computed for subset category with <10 patients in at least one treatment group. BICR, blinded independent central review; chemo, chemotherapy; CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, oxaliplatin + leucovorin + fluorouracil; GC, gastric cancer; GEJC, gastroesophageal junction cancer; LAG-3, lymphocyte-activation gene 3; NIVO, nivolumab; ORR, objective response rate; RELA, relatlimab; XELOX, oxaliplatin + capecitabine.